Category

Origins and discovery

31 plain-language articles on origins and discovery — the physiology, the compounds, and what the evidence actually shows.

31 articles

AI-designed peptides — how computational protein design is changing drug discoveryIn November 2020, a system called AlphaFold2 solved a problem that structural biologists had spent fifty years treating as practically unsolvable. Given a protein's amino acid sequence, it predicted the three-dimensional shape that protein would fold into — with an accuracy that stunned the field, matched experimental crystallography in many cases, and made the entire Protein Data Bank look like a starting point rather than an endpoint. The news traveled fast, landed in the scientific press like a thunderclap, and then did what major scientific advances usually do: it started rewriting the assumptions underneath a whole industry.10 min read AOD-9604 — the human growth hormone fragment Australian biotech designed to skip the anabolic sideIn the early 1990s, a biochemist at Monash University in Melbourne named Frank Ng was working on a problem that had frustrated pharmaceutical researchers for decades: human growth hormone is a molecule that does too many things at once. It promotes fat breakdown. It drives muscle and tissue growth. It stimulates the liver to produce IGF-1, a powerful growth factor. It influences glucose metabolism. It affects bone density, skin thickness, cardiac function, and half a dozen other systems. The breadth of its activity was both its appeal and its fundamental commercial and clinical problem — because when you give someone exogenous HGH to get one of those effects, you get the others too, and some of them are effects you don't want.8 min read Belgian Blue cattle, myostatin knockouts, and the human translation questionSomewhere in rural Belgium in the mid-nineteenth century, breeders began selecting cattle for an unusual trait. The animals they favored carried more muscle than normal cattle in a way that was immediately visible — thicker shoulders, a distinctive rounded rear, musculature that seemed to press outward against the skin. The breeders did not know why some animals carried this trait and others did not. They knew only that it bred true in certain lines, that it produced beef in extraordinary quantity, and that the calves born from these unions were sometimes too large to be born without human assistance. They kept selecting anyway. They were, without knowing it, selectively concentrating a loss-of-function mutation in a gene that would not be identified for another century.8 min read The biohacker movement — from Quantified Self to peptide stacksIn 2007, Kevin Kelly — co-founder of Wired magazine, former editor, one of the more restless and prescient minds in tech culture — started holding what he called "Show and Tell" gatherings in San Francisco. People came to talk about tracking things about themselves: steps, sleep cycles, caloric intake, mood scores, blood glucose readings taken with consumer glucometers that were really designed for diabetics. The gatherings attracted software engineers, product designers, academics, and people who were simply curious about the numbers they were generating. They were not yet calling themselves biohackers. They were calling it Quantified Self.10 min read The bodybuilding peptide underground — a history nobody wroteThe forum post was dated 2003. The user went by a handle that combined a number and an animal. He'd been running a protocol of GHRP-6 and CJC-1295 for twelve weeks, dosing before bed, and he was reporting on sleep quality, appetite, and recovery between sessions. He'd gotten the peptides from a research chemical company in eastern Europe. He wasn't sure about the purity. He had no bloodwork. He was dosing based on a protocol he'd assembled from three other forum threads, one of which cited a paper he hadn't read. He said it was working. He said he thought he understood why.11 min read How BPC-157 was found in human gastric juiceIn 1991, a gastroenterologist at the University of Zagreb was thinking about the stomach lining and asking what seemed like an obvious question that nobody had quite posed directly. The stomach is a hostile environment — hydrochloric acid, pepsin, mechanical stress, constant exposure to whatever comes down from above. And yet the gastric mucosa heals. It heals constantly, reflexively, under conditions that would destroy most tissues in the body. Predrag Sikiric thought there must be something in gastric juice itself doing that work. Not just a passive barrier, but an active signal. Something the stomach was secreting to protect itself.8 min read The neuropeptide universe — from Semax and Cortexin to Dihexa, the cognitive enhancement field that doesn't show up in US pharmaIn 1972, a Soviet neuropharmacologist named Nikolai Koval published early research on neuropeptide fragments derived from ACTH — adrenocorticotropic hormone — and their effects on memory and learning in animal models. He was not working in a vacuum. Across Soviet research institutes, the emerging field of neuropeptide biology was being pursued with particular intensity, partly because it offered a theoretical alternative to the receptor-agonist pharmacology dominating Western drug development, and partly because Soviet research programs were structured around different institutional priorities, different funding pressures, and different timelines than their Western counterparts. The compounds that emerged from that tradition — Semax, Selank, Cortexin, Cortagen, Pinealon, and others — are now used clinically in Russia and parts of Eastern Europe. In the United States, most physicians have never heard of them.9 min read The David Sinclair NAD+ story — hype, evidence, honest assessmentIn the late 1990s, a graduate student named David Sinclair was working in Lenny Guarente's lab at MIT, trying to understand why yeast cells age. The answer his experiments pointed toward involved a protein called Sir2 — Silent Information Regulator 2. In yeast, Sir2 controlled whether certain genomic regions were transcriptionally active or silenced, and its activity appeared to be linked to lifespan. When you increased Sir2 expression in yeast, the cells lived longer. When you inhibited it, they lived less long. Sinclair went on to characterize Sir2 and its mammalian cousins, the sirtuins, as what he would eventually describe as a master regulatory system of aging — a set of molecular sensors that respond to cellular stress and energy status and govern whether cells survive, repair themselves, or succumb to aging-associated dysfunction.9 min read Epitalon and the Khavinson school — the deeper Russian research historyIn the mid-1970s, in Leningrad — not yet St. Petersburg again — a Soviet military physician named Vladimir Khavinson began a research program that would eventually span five decades and produce a body of work that most Western scientists have never read. The institutional home was the Military Medical Academy, a prestigious institution with origins dating to the eighteenth century, where Khavinson was working in the department of pathophysiology. The question he was pursuing was not fashionable by Western standards: it was whether the aging process could be slowed through targeted peptide administration. Not reversed, not indefinitely extended — slowed. The Soviet framing of the problem was practical, almost industrial. What compounds could preserve the functional capacity of soldiers, cosmonauts, and aging populations? The research that followed was shaped by that institutional context.10 min read Epitalon and the telomere conversation — what Khavinson's research actually showedIn the 1970s, Soviet medicine was running a parallel research program that Western researchers mostly couldn't read. Not because it was hidden — it was published, regularly, in Soviet and Russian journals — but because the language barrier was real, the institutional infrastructure for translation was limited, and the scientific exchange between Soviet and Western research communities was episodic at best. One of the things being published in that parallel program was a body of work on peptide bioregulators: short peptides derived from organ tissues that appeared, in the laboratory and in animal studies, to exert regulatory effects on specific biological systems. The researcher at the center of this work was Vladimir Khavinson, working at the Institute of Bioregulation and Gerontology in St. Petersburg — the institution that would, decades later, produce the compound that sparked a still-ongoing conversation in longevity biology.9 min read Exenatide and the gila monster — how the GLP-1 family startedThe gila monster doesn't eat much. A large meal — a bird's egg, a small mammal, a clutch of nestlings — can sustain it for weeks. It lives in the Sonoran Desert and the Mojave, in rocky terrain where food is scarce and unpredictable, and its metabolism has spent millions of years adapting to this reality. When it does eat, its blood glucose management has to be precise: a spike of glucose into a system that isn't continuously calibrated for meals would be dangerous. And yet the gila monster manages this without a meal plan, without continuous glucose monitoring, without insulin injections. It manages it with chemistry that its body produces and that, it turns out, looks remarkably like a hormone humans also produce — just improved. Sturdier. Built for the long intervals between meals.8 min read The GLP-1 discovery deeper history — Holst, Mojsov, and the science before the drugIn 1982, Jens Juul Holst was working in a basement laboratory at the University of Copenhagen, trying to understand what the gut did with glucose. Not what happened in the bloodstream afterward. Not what the pancreas produced. What the gut itself was doing — the biochemical signaling that happened in the intestinal wall in the seconds and minutes after food arrived. It was methodical, unglamorous work: isolating intestinal tissue from pigs and dogs, running extracts through high-performance liquid chromatography, measuring immunoreactive peptide fractions that no one had fully characterized. One of those fractions kept showing up in a way that suggested it was derived from the glucagon gene but wasn't glucagon. It behaved differently. It appeared in the intestine rather than the pancreas. And it seemed, in preliminary experiments, to do something interesting to insulin secretion.11 min read The history of GLP-1 research — from Habener and Drucker to OzempicIn 1987, a paper appeared in the Proceedings of the National Academy of Sciences describing the structure of proglucagon — the precursor protein that the body cleaves into multiple peptides depending on which tissue is doing the cleaving. Joel Habener's laboratory at Massachusetts General Hospital had worked out the sequence and identified, buried inside it, two peptides that looked like distant relatives of glucagon. They called them glucagon-like peptide-1 and glucagon-like peptide-2. The paper was read by people who study pancreatic hormones. It was not a cultural event. Nobody wrote about it in a newspaper. The molecule's future wasn't legible yet from what Habener's group knew at that point.9 min read Growth hormone — the cadaver-extracted hormone, the CJD tragedy, and the recombinant breakthroughIn 1985, a neurologist in California diagnosed a 20-year-old with a disease that typically strikes people in their sixties. The patient presented with dementia and involuntary movements — the progressive and devastating deterioration of Creutzfeldt-Jakob disease, a prion disorder with no treatment and no survival. But this patient was not in his sixties. He had received injections of human growth hormone as a child, for a growth deficiency, through a program that had been running for two decades. He was one of the first. He would not be the last.6 min read IGF-1 and bodybuilding — the history of an underground drugIn the mid-1980s, a certain kind of physique started appearing on competitive bodybuilding stages that hadn't been there before. The bodies were larger, yes — that trajectory had been underway since the 1950s — but the change in the 1980s was qualitative, not just quantitative. The abdomens were distended in ways that seemed to contradict the body fat percentages on stage. The internal density was different. The growth had a character that steroids alone, which the sport had used openly since the 1960s, didn't quite explain. Competitors and coaches began whispering about growth hormone, which had recently become available in synthetic recombinant form. They were right about GH. But they were, in a specific technical sense, also wrong about what was doing most of the work.8 min read Insulin in Toronto, 1921 — the discovery that started peptide pharmacologyIt was past two in the morning when Frederick Banting read the paper. November 1920, in his rented room in London, Ontario, where he'd opened a small surgical practice that wasn't filling up. Banting was 29, trained as a surgeon, failing at attracting patients in a city that had no shortage of them, and moonlighting as a part-time lecturer in physiology at the University of Western Ontario to cover rent. The paper was by Moses Barron, published in Surgery, Gynecology and Obstetrics, describing the pancreatic duct and what happened when it was ligated. The acinar cells — the cells responsible for digestive enzymes — degenerated. The islets of Langerhans, packed into the pancreas like small islands, survived. Banting underlined something and wrote in the margin. Then he wrote in his notebook: "Diabetus. Ligate pancreatic ducts of dog. Keep dogs alive till acini degenerate leaving Islets. Try to isolate the internal secretion of these to relieve glycosurea."6 min read The longevity movement — from caloric restriction in mice to Ozempic on TikTokIn 1993, a researcher named Cynthia Kenyon walked into a genetics seminar at UC San Francisco and announced that she had doubled the lifespan of a roundworm. Not extended it modestly. Doubled it. The mutation was in a single gene, daf-2, which encodes a receptor for an insulin-like growth factor. The worms lived twice as long, moved like younger worms, and showed no obvious tradeoffs. The audience, by several accounts, went quiet in a way that academic audiences rarely do. The implication was too large to hold comfortably: that aging itself might be a regulated process. That it might be intervened upon.10 min read Melanotan I (afamelanotide) — from Arizona research lab to FDA-approved for EPPThe University of Arizona sits in one of the sunniest cities in North America. Tucson averages over 350 days of sunshine per year. It is the kind of place where people who move from cloudier climates take a particular pleasure in the light, and where dermatologists see, with regularity, what too much UV does to human skin over decades. It is perhaps fitting, then, that in the early 1980s a research lab at the University of Arizona began asking a question that seems obvious in retrospect but had not yet been seriously pursued: if the body already has a mechanism to protect itself from UV damage, could you turn that mechanism up pharmacologically?8 min read Melanotan II and the bodybuilding split — how a tanning research peptide became a libido drugThere is a particular category of scientific discovery that gets described, with some frequency, as accidental. The word undersells what usually happened, which is not randomness but observation: someone noticed something unexpected and, instead of explaining it away, wrote it down and asked what it meant. The discovery that launched Melanotan II's trajectory from research compound to gray-market phenomenon falls into that category. The researchers were looking for tanning. They found something else first.8 min read MK-677 — the oral ghrelin mimetic Merck shelved and the community kept aliveA researcher in a Merck lab in the early 1990s was thinking about a problem that sounds almost mundane: needles. Not their danger, not their cost, but their relentlessness. If you want to restore growth hormone signaling in an elderly person — someone in their seventies with a hip fracture and declining lean mass and the kind of fatigue that makes rehabilitation nearly impossible — you have to inject them. Daily. With a compound that degrades in the gut, that can't be swallowed, that requires a cold chain and a prescription and a willingness to tolerate subcutaneous injections for the foreseeable future. In a frail elderly population, that's not a clinical protocol. It's a fantasy.8 min read MOTS-c — the peptide your mitochondria write themselvesIn 2015, a research team at the University of Southern California published a paper in Cell Metabolism that quietly changed the way biologists had to think about the mitochondrion. The paper was not loudly announced outside specialist circles. It didn't generate the cultural noise that cancer immunotherapy or CRISPR news generated that same year. But what Pinchas Cohen, Changhan Lee, and their colleagues described was a genuine reclassification — a finding that required updating a story about cellular biology that had been told, largely without revision, since the 1960s.8 min read GHRP-2, GHRP-6, Hexarelin — the older GH-releasing peptides and why newer ones replaced themIt's 1977, and a researcher at Tulane University named Cyril Bowers is trying to understand something strange. He's been working with synthetic enkephalin analogs — small opiate-like peptides — and he notices that some of them, unexpectedly, are causing growth hormone to rise in his experimental subjects. Not because they're growth hormone. Not because they mimic growth hormone-releasing hormone. For some reason, these structurally unrelated molecules are hitting a switch that growth hormone researchers hadn't known existed.6 min read Peptide drug conjugates — the targeted delivery revolution underwayA chemotherapy drug administered conventionally travels everywhere. It enters the bloodstream, circulates, and kills cells that are dividing rapidly — which is most of what makes cancer cells vulnerable and most of what makes conventional chemotherapy brutal. The cells lining the gut divide rapidly. Hair follicle cells divide rapidly. Bone marrow produces new blood cells through rapid division. Chemotherapy doesn't distinguish. The drug is poison delivered systemically, and the art of chemotherapy dosing has always been the art of finding the highest dose the patient can survive while hoping the tumor can't.7 min read How peptides became a drug category — from insulin to GLP-1, one hundred years of peptide pharmacologyIt is January 11, 1922, and a fourteen-year-old boy named Leonard Thompson is lying in a Toronto hospital bed. He has had type 1 diabetes for two years. He weighs sixty-five pounds. His blood sugar is five hundred milligrams per deciliter. He has been on a severe starvation diet — the only management available — which is buying him weeks. Frederick Banting and Charles Best inject him with a partially purified extract from canine pancreatic tissue. He goes into anaphylactic shock. The extract is crude, contaminated, and the dose is poorly characterized. They stop. They spend the next twelve days refining the preparation with a biochemist named James Collip. On January 23, they inject Thompson again. Within twenty-four hours his blood sugar drops to normal. The boy who was starving in a Toronto hospital lives for another thirteen years before dying, not from diabetes, of pneumonia. In those thirteen years he is the first human being to survive a disease that had been uniformly fatal in juveniles since antiquity.12 min read Peptide research during the Cold War — the Soviet biology the West didn't seeIn the mid-1970s, in a research institute on Kirochnaya Street in Leningrad, a scientist named Vladimir Khavinson was developing a hypothesis about aging that Western gerontologists would not encounter for another twenty years. The hypothesis was not, at its core, different from ideas circulating in American and European labs about cellular senescence and protein regulation. But the experimental program Khavinson built around it — isolating short peptide fractions from organ tissues and testing them for bioregulatory effects — proceeded in near-total isolation from Western pharmacology, published in Russian-language journals with limited international circulation, funded by the Soviet military through channels that made some of the research formally classified, and shaped by institutional traditions that valued multi-organ systems thinking over the single-target drug development that dominated Western pharmaceutical methodology.10 min read The decades arc of peptide research — what's changed and what's recurredIn 1921, Frederick Banting was a twenty-nine-year-old Canadian surgeon with a research idea that his department chairman at the University of Toronto considered unpromising. The idea was that insulin — the pancreatic secretion that had been hypothesized for decades to regulate blood sugar — could be isolated and used to treat diabetic patients who would otherwise die. Banting had read a paper about the pancreatic islet cells and had a method in mind for isolating their secretion without contaminating it with the destructive enzymes produced by surrounding tissue. His chairman, J.J.R. Macleod, gave him a laboratory, a summer, a young biochemist named Charles Best, and a collection of experimental dogs. By the end of that summer, the extract worked in dogs. By January 1922, Leonard Thompson — a fourteen-year-old diabetic patient near death in Toronto General Hospital — received the first injection in a human being. By the end of the century, the compound that Banting and Best partially purified in that summer laboratory had been re-engineered through recombinant DNA technology, was being produced by bacteria carrying a human gene, and was keeping approximately nine million Americans alive.11 min read PT-141 — the peptide that was supposed to be a tanning drugIt was 1980-something in a University of Arizona lab, and a pharmacologist named Mac Hadley had a genuinely reasonable idea: if sunlight causes melanin production by triggering alpha-melanocyte-stimulating hormone, could you give people a synthetic version of that hormone and let them tan without UV exposure? Protect skin from cancer by inducing its own protection. The logic was clean. The molecule they needed — a synthetic analog of α-MSH — was the kind of thing Victor Hruby's lab was built to design.8 min read Why Russian nootropics never crossed the Atlantic — Semax, Selank, Cortexin, and the regulatory gapSomewhere in a Russian neurological clinic in 1999, a physician is writing a Semax prescription for a patient recovering from ischemic stroke. This is unremarkable in that context — Semax has been an approved pharmaceutical in Russia since 1994, used routinely in neurology wards, prescribed by ordinary physicians for stroke recovery and cognitive decline, with a safety record built across millions of patients. A few thousand miles away, in an American neurologist's office, the same physician has never heard the word. It does not appear in any clinical guideline he was trained on. It does not appear in UpToDate. It does not appear anywhere in the evidence base his institution recognizes as existing.8 min read The Russian peptide bioregulator tradition — Khavinson and the St. Petersburg schoolThe year is 1971 and a young Soviet military physician named Vladimir Khavinson has been handed an unusual problem. He is stationed with the Red Army, and the soldiers he is treating are aging poorly — not in the civilian sense, but in the sense that matters to a military institution: premature functional decline, accelerating physiological deterioration in men who should be at the height of their capacity. The question put to Khavinson and his colleagues was essentially a pharmacological version of a military logistics problem: can the biology of aging be managed the way other logistical problems are managed? Can you find the signal the body uses to maintain itself, and supply more of it when the body starts running short?9 min read The Amazon rainforest, snake venom, and the discovery of ACE inhibitorsThe workers in rural Brazil who were bitten by the Bothrops jararaca, the lancehead pit viper, did not die from blood pressure. They died from hemorrhage — the snake's venom is hemotoxic and causes catastrophic disruption to the coagulation cascade. What the surviving bite victims noticed, and what eventually caught a pharmacologist's attention in the early 1960s, was a different effect: profound, sudden hypotension. Their blood pressure dropped dramatically after envenomation. Something in the venom was doing something specific to the vasculature. The question of what that something was, pursued through a series of unglamorous and painstaking biochemical extractions over the following years, produced one of the most consequential drug classes in the history of cardiovascular medicine.10 min read Thymosin Alpha-1 — the immune modulator the US never approved but 35 countries didIn the mid-1960s, a young scientist named Allan Goldstein arrived at Albert Einstein College of Medicine with an unusual conviction: that the thymus gland — the small, butterfly-shaped organ that sits behind the sternum and had long been considered a curiosity of childhood anatomy — was doing something important that medicine had not yet named. The thymus was known to shrink with age, to be largest in early childhood and nearly invisible in adults. Most physicians considered it vestigial in adults, an organ that had done whatever it needed to do and then quietly retired. Goldstein thought otherwise.8 min read

← All articles